

Synthesis of New Pyridazinone Derivatives and their Affinity Towards α_1 – α_2 -Adrenoceptors

Stefano Corsano,^{a,*} Giovannella Strappaghetti,^a Roberta Barbaro,^a Gino Giannaccini,^b Laura Betti^b and Antonio Lucacchini^b

^a*Istituto di Chimica e Tecnologia del Farmaco, Università di Perugia, Via del Liceo 1, 06123 Perugia, Italy*

^b*Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy*

Received 2 October 1998; accepted 18 January 1999


Abstract—A series of 3(2*H*)-pyridazinone derivatives was evaluated for their affinity in vitro towards α_1 – α_2 -adrenoceptors by radioligand receptor binding assays. All target compounds showed good affinities for the α_1 -adrenoceptor (with K_i values in the subnanomolar range), and a gradual increase in affinity was observed by increasing the polymethylene chain length of this series up to a maximum of six and seven carbon atoms, when the fragment 4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl is linked in 5 position of the 3(2*H*)-pyridazinone ring, while a slight decrease was found for the higher homologues. Increasing the chain length when the 4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl group is linked in 6 position of the 3(2*H*)-pyridazinone ring, had a different effect: there is the highest affinity when the polymethylene chain is of four carbon atoms. The alkylic chain, a spacer between the two major constituents of the molecule, can influence the affinity and the selectivity. © 1999 Elsevier Science Ltd. All rights reserved.

Introduction

The α_1 – α_2 -adrenoceptors (α_1 AR and α_2 AR) are members of the superfamily of G protein coupled receptors. Molecular cloning studies^{1,2} have shown that these receptors have many common features which could reflect their similar mechanisms of action.

In recent years, the search for new α_1 -adrenoceptor antagonists has increased, in parallel with the development of postsynaptically selective α -adrenoceptor antagonists, due to their importance in the treatment of hypertension³ and of benign prostatic hypertrophy⁴ (BPH).

In the course of our studies on 3(2*H*)-pyridazinone derivatives as potential antagonists of the α -adrenoceptor, we have recently synthesized compounds **1**⁵ and **1a**,⁶ which showed good activity towards α_1 -adrenoceptor. It is well known that the 1-arylpiperazines and their 4-alkyl derivatives, such as Urapidil and SL8905⁷ (**2**), are postsynaptic α -blockers with activity on BPH.



The objective of our work has been the synthesis of new compounds that are highly selective towards the α_1 -receptor, as potential antihypertensive drugs, and as molecular probes for the study of binding sites. In this paper we report the synthesis and biological affinity of compounds in which the 3(2*H*)-pyridazinone ring has been linked in the 2-position with variations of 1-aryl-piperazine, by a chain variable for 2 to 8 carbon atoms.

Chemistry


The synthesis of novel pyridazinone derivatives **3–28** are reported in Scheme 1.

Compounds **3**⁸ and **10** were prepared by alkylation from **30a** with 1-(2-methoxyphenyl)-piperazine or 1-(2-chlorophenyl)-piperazine respectively in isoamyl alcohol and sodium carbonate. Compound **30a** was prepared by

Key words: Pyridazinone; affinity α_1 , α_2 -blocking; 1-arylpiperazine and RAS.

Abbreviations: TBAB = tetrabutyl ammonium bromide; DMF = *N,N*-Dimethylformamide.

*Corresponding author.



Scheme 1.

treatment of the 4-chloro-5-{4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone **1**⁵ with 1,2-dibromoethane using benzene, TBAB and KOH according to the method of Yamada et al.⁹

Compounds **4**, **11**, **18** and **24** were prepared by alkylation of the 4-chloro-5-{4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**1**) or 6-{4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**1a**)⁶ with 1-(2-methoxyphenyl)-4-(3-chloropropyl)-piperazine (**29c**) or 1-(2-chlorophenyl)-4-(3-chloropropyl)-piperazine (**29d**), in dry ethanol and sodium hydroxide pellets. Intermediates **29c** and **29d** were prepared using the method of J. Bourdais¹⁰ in DMF in the presence of potassium carbonate.

Compounds **17** and **23** were prepared, using as starting compound **1a** by alkylation with 1-(2-methoxyphenyl)-4-(2-chloroethyl)-piperazine (**29a**) or 1-(2-chlorophenyl)-4-(2-chloroethyl)-piperazine (**29b**) (prepared by the method of J. Bourdais)¹⁰ in dry ethanol and sodium hydroxide pellets, respectively.

Alkylation of compound **1** with the dihalogenates with polymethylene chain length from four to eight carbon atoms, in acetone and potassium carbonate, gave the intermediates **30b–f**, which by reacting with 1-(2-methoxyphenyl)-piperazine or 1-(2-chlorophenyl)-piperazine gave the compounds **5–9**, **12–16**, respectively.

For the synthesis of compounds **19–22** and **25–28** the same procedure described above was used. Finally, the intermediates **31a–d** were prepared using the method described for compounds **30b–f**.

Pharmacology

The pharmacological profile of compounds **3–28** was evaluated for their affinities towards α_1 - and α_2 -adrenoceptors by determining for each compound the ability to displace [³H]-prazosin or [³H]-rauwolscine, respectively, from specific binding sites on rat cerebral cortex.


Results and Discussion

In Table 1a–b are reported competition binding experiments of compounds **3–28**.

Relative to the K_i values observed for the α_1 -AR and α_2 -AR, show that, all the synthesized compounds have higher affinities towards the α_1 -adrenoceptor than towards the α_2 -adrenoceptor. In the series a gradual increase in affinity was observed by promoting the polymethylene chain length up to a maximum of six or seven carbon atoms, when the fragment 4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl is linked in 5 position of the 3(2*H*)-pyridazinone ring (compounds **7**, **8** and **14**, **15**), while a slight decrease was found for the higher homologues **9** and **16**. Increasing the chain length when the 4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl group was linked in 6 position of the 3(2*H*)-pyridazinone ring had a different effect: there is the highest affinity when the polymethylene chain has four carbon atoms (compounds **19** and **25**). Thus, the position of the fragment 4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl influences the affinity and it is strictly dependent on the carbon-chain length. In the series of compounds **3–16** a peak potency was observed with a six or seven carbon chain, while in


Table 1. Affinity towards α_1 - and α_2 -adrenoceptors

(a)



Compound	n	X	$K_i \alpha_1$ (nM)	$K_i \alpha_2$ (nM)	Ratio α_2/α_1
3	2	-OCH ₃	16.0 ± 1.7	409.0 ± 35.7	25.5
4	3	-OCH ₃	14.5 ± 1.3	245.0 ± 25.3	17.0
5	4	-OCH ₃	4.3 ± 0.3	230.0 ± 20.0	53.0
6	5	-OCH ₃	3.9 ± 0.2	15.0 ± 1.9	3.8
7	6	-OCH ₃	1.5 ± 0.1	3.5 ± 0.4	2.3
8	7	-OCH ₃	1.4 ± 0.1	4.6 ± 0.5	3.2
9	8	-OCH ₃	3.5 ± 0.4	22.7 ± 3.0	6.5
10	2	-Cl	58.8 ± 3.7	292.3 ± 30.2	5.0
11	3	-Cl	27.8 ± 3.0	219.0 ± 15.8	7.8
12	4	-Cl	10.0 ± 1.5	39.3 ± 5.3	4.0
13	5	-Cl	4.5 ± 0.2	29.0 ± 4.5	6.4
14	6	-Cl	4.2 ± 0.6	25.2 ± 3.8	6.0
15	7	-Cl	2.7 ± 0.3	7.4 ± 0.5	2.7
16	8	-Cl	5.6 ± 0.7	22.8 ± 2.5	4.0
Prazosin			0.24 ± 0.05		
Rauwolscline				4.0 ± 0.3	

(b)



17	2	-OCH ₃	38.0 ± 5.0	1261.0 ± 210.0	33.2
18	3	-OCH ₃	73. ± 0.6	254.0 ± 40.3	34.8
19	4	-OCH ₃	0.6 ± 0.1	62.0 ± 8.0	103.3
20	5	-OCH ₃	12.9 ± 1.5	69.8 ± 9.2	5.4
21	6	-OCH ₃	7.0 ± 0.8	71.8 ± 6.3	10.2
22	7	-OCH ₃	2.3 ± 0.2	45.8 ± 6.3	20.0
23	2	-Cl	18.0 ± 2.0	370.0 ± 50.2	20.5
24	3	-Cl	6.8 ± 0.6	316.0 ± 40.3	46.5
25	4	-Cl	0.8 ± 0.1	69.4 ± 6.0	86.7
26	5	-Cl	7.0 ± 0.9	138.0 ± 25.0	20.0
27	6	-Cl	8.4 ± 1.2	138.8 ± 20.3	16.5
28	7	-Cl	15.0 ± 2.5	139.0 ± 15.3	9.3
Prasosin			0.24 ± 0.05		
Rauwolscline				4.0 ± 0.3	

The K_i binding data were calculated as described in the Experimental section. The K_i values are mean ± SD of series separate assays, each performed in triplicate. Inhibition constants (K_i) were calculated according to the equation of Cheng and Prousoff¹¹ $K_i = IC_{50}/1 + (L/K_d)$ when [L] is the ligand concentration and K_d is dissociation constant. K_d of [³H]-prazosin binding to rat cortex membranes was 0.24 nM (α_1) and K_d of [³H]-rauwolscline binding to rat cortex membranes was 4 nM (α_2).

the series of **17–28** the highest affinity was observed when the chain had four carbon atoms. It is evident from these pharmacological results that the presence of a methoxy group in the *ortho* position of the arylpiperazine fragment increases the affinity more than a chlorine atom. Moreover comparing the ratios of the K_i values (α_2/α_1), one can readily see that the length of the alkyl spacer has an effect on selectivity for both the 5- and 6-substituent methoxy series (for example compound **19** shows the highest selectivity). Similar results have been obtained for the 6-substituent chlorine series and little effect was observed for 5-substituted chlorine series.

In conclusion, the length of the alkyl chain, a spacer between the two major constituents of the molecule, can influence the affinity and the selectivity.

Experimental Protocols

Biological methods

α_1 -Receptor binding. Rat cerebral cortex was homogenized in 20 volumes ice-cold 50 mM Tris-HCl buffer at pH 7.7 containing 5 mM EDTA (buffer T₁) in an

ultra-turrax homogenizer. The homogenate was centrifuged at 48000 *g* for 15 min at 4 °C. The pellet (P₁) was suspended in 20 volumes of ice-cold buffer T₁. It was then homogenized and centrifuged at 48000 *g* for 15 min at 4 °C. The resulting pellet (P₂) was frozen at –80 °C until the time of assay.

The pellet was suspended in 20 volumes of ice-cold 50 mM Tris–HCl buffer at pH 7.7 (T₂ buffer) and α_1 binding assay was performed in triplicate by incubating at 25 °C for 60 min in 1 mL T₂ buffer containing aliquots of the membrane fraction (0.2–0.3 mg protein) and 0.1 nM [³H]-prazosin in the absence or presence of unlabeled 1 μ M prazosin. The binding reaction was terminated by filtering through Whatman GF/C glass fiber filters under suction and washing twice with 5 mL ice-cold Tris buffer. The filters were placed in scintillation vials and 4 mL Ultima Gold MN Cocktail-Packard solvent scintillation fluid was added. The radioactivity was counted with an Packard 1600 TR scintillation counter. Specific binding was obtained by subtracting non-specific binding from total binding and was approximated to 85–90% of the total binding.

α_2 -Receptor binding. Cerebral cortex was dissected from rat brain and the tissue was homogenized in 20 volumes of ice-cold 50 mM Tris–HCl buffer at pH 7.7 containing 5 mM EDTA, as reported above (buffer T₁). The homogenate was centrifuged at 48000 *g* for 15 min at 4 °C. The resulting pellet was diluted in 20 volumes of 50 mM Tris–HCl buffer at pH 7.7 and used in the binding assay.

Binding assay was performed in triplicate, by incubating aliquots of the membrane fraction (0.2–0.3 mg protein) in Tris–HCl buffer at pH 7.7 with approximately 2 nM [³H]-rauwolscine in a final volume of 1 mL. Incubation was carried out at 25 °C for 60 min. Non-specific binding was defined in the presence of 10 μ M rauwolscine. The binding reaction was concluded by filtration through Whatman GF/C glass fiber filters under reduced pressure. Filters were washed four times with 5 mL aliquots of ice-cold buffer and placed in scintillation vials. Specific binding was obtained by subtracting non specific binding from total binding and approximated to 85–90% of total binding. The receptor-bound radioactivity was measured as described above.

Compounds were dissolved in buffer or DMSO (buffer/concentration of 2%) and added to the assay mixture. A blank experiment was carried out to determine the effect of the solvent on binding.

Protein estimation was based on a reported method,¹² after solubilization with 0.75 N sodium hydroxide, using bovine serum albumin as standard.

The concentration of tested compound that produces 50% inhibition of specific [³H]-prazosin or [³H]-rauwolscine binding (IC₅₀) was determined by log-probit analysis with seven concentrations of the displacer, each performed in triplicate. Inhibition constants (*K_i*) were calculated according to the equation:¹¹ $K_i = IC_{50}/1 + ([L]/K_d)$ where [L] is the ligand concentration and *K_d* its

dissociation constant. *K_d* of [³H]-prazosin binding to cortex membranes was 0.24 nM (α_1) and *K_d* of [³H]-rauwolscine binding to cortex membranes was 4 nM (α_2)

Experimental

Melting points were determined using a Kofler hot-stage apparatus and are uncorrected. The NMR spectra were recorded with a Bruker AC 200 MHz instrument in the solvent indicated below. The chemical shift values (ppm) are relative to tetramethylsilane as internal standard. Elemental analyses are within $\pm 0.4\%$ of theoretical values. Precoated Kiesegel 60 F₂₅₄ plates (Merck) were used for TLC. The corresponding hydrochlorides were prepared by bubbling dry HCl into the dry solution of the compound.

General method A

4-Chloro-2-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (3). A mixture of (1 g, 2.3 mmol) of 4-chloro-2-(2-chloroethyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**30a**), (0.45 g, 2.3 mmol) of 1-(2-methoxyphenyl)-piperazine, (0.3 g, 2.9 mmol) of dry sodium carbonate in 40 mL of iso-amyl alcohol, was refluxed under stirring for 24 h, after filtration, the solvent was removed under reduced pressure, and the residue was purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (4/96) to give a dense oil, (50%). ¹H NMR (CDCl₃) δ : 2.60–2.95 (m, 12H, 8H-pip., 2CH₂), 3.05–3.15 (m, 4H, H-pip.), 3.40–3.55 (m, 4H, H-pip.), 3.85 (s, 6H, 2-OCH₃), 4.20 (t, *J* = 6 Hz, 2H, CH₂), 4.35 (t, *J* = 6 Hz, 2H, CH₂), 6.80–7.00 (m, 8H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 128–129 °C. Anal. calcd for C₃₀H₃₉ClN₆O₄. 2HCl: C, 54.93; H, 6.25; N, 12.81, found: C, 54.65; H, 6.04; N, 12.54.

Compounds **5–10**, **12–16** were synthesized following general method A.

4-Chloro-2-{4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (5). By 4-chloro-2-(4-chlorobutyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**30b**) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (7/93), a dense oil was obtained (60%), ¹H NMR (CDCl₃) δ : 1.50–1.65 (m, 2H, CH₂), 1.75–1.90 (m, 2H, CH₂), 2.50 (t, *J* = 8 Hz, 2H, CH₂), 2.60–2.80 (m, 8H, H-pip.), 2.90 (t, *J* = 6 Hz, 2H, CH₂), 3.05–3.15 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.85 (s, 6H, 2OCH₃), 4.10–4.30 (m, 4H, 2CH₂), 6.80–7.00 (m, 8H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 126–128 °C. Anal. calcd for C₃₂H₄₃ClN₆O₄. 3HCl: C, 53.35; H, 6.39; N, 11.67, found: C, 53.31; H, 6.78; N, 11.36.

4-Chloro-2-{5-[4-(2-methoxyphenyl)-1-piperazinyl]pentyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (6). From 4-chloro-2-(5-bromopentyl)-5-{4-

[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30c**) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (5/95), a dense oil was obtained (30%). ¹H NMR (CDCl₃) δ: 1.35–1.45 (m, 2H, CH₂), 1.55–1.70 (m, 2H, CH₂), 1.75–1.90 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.55–2.65 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.15 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.85 (s, 6H, 2-OCH₃), 4.10–4.20 (m, 4H, 2CH₂), 6.80–7.00 (m, 8H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 95–98 °C. Anal. calcd for C₃₃H₄₅ClN₆O₄ · 3HCl: C, 53.96; H, 6.54; N, 11.44, found: C, 54.20; H, 6.75; N, 11.65.

4-Chloro-2-{6-[4-(2-methoxyphenyl)-1-piperazinyl]hexyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (7). From 4-chloro-2-(6-chlorohexyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30d**) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (6/94), a dense oil was obtained (69%). ¹H NMR (CDCl₃) δ: 1.30–1.40 (m, 4H, 2CH₂), 1.50–1.65 (m, 2H, CH₂), 1.70–1.85 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.55–2.75 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.20 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.85 (s, 6H, 2OCH₃), 4.10–4.20 (m, 4H, 2CH₂), 6.80–7.00 (m, 8H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 138–140 °C. Anal. calcd for C₃₄H₄₇ClN₆O₄ · 3HCl: C, 54.56; H, 6.68; N, 11.20, found: C, 55.00; H, 6.91; N, 11.32.

4-Chloro-2-{7-[4-(2-methoxyphenyl)-1-piperazinyl]heptyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (8). From 4-chloro-2-(7-bromoheptyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30e**) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (6/94), a dense oil was obtained (75%). ¹H NMR (CDCl₃) δ: 1.30–1.45 (m, 6H, 3CH₂), 1.50–1.60 (m, 2H, CH₂), 1.70–1.85 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.70–2.80 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.20 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.85 (s, 6H, 2-OCH₃), 4.10–4.25 (m, 4H, 2CH₂), 6.80–7.00 (m, 8H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 125–128 °C. Anal. calcd for C₃₅H₄₉ClN₆O₄ · 3HCl: C, 55.35; H, 6.45; N, 11.07, found: C, 55.36; H, 7.00; N, 10.95.

4-Chloro-2-{8-[4-(2-methoxyphenyl)-1-piperazinyl]octyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (9). From 4-chloro-2-(8-chlorooctyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30f**) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (7/93), a dense oil was obtained (40%). ¹H NMR (CDCl₃) δ: 1.30–1.40 (m, 8H, 4CH₂), 1.50–1.60 (m, 2H, CH₂), 1.65–1.75 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.60–2.70 (m, 8H, H-pip.), 2.90 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.20 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.85 (s, 6H, 2OCH₃), 4.10–4.30 (m, 4H, 2CH₂), 6.70–7.00 (m, 8H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride

is hygroscopic. Anal. calcd for C₃₆H₅₁ClN₆O₄ · 3HCl: C, 55.90; H, 6.98; N, 10.87, found: C, 55.78; H, 6.60; N, 10.73.

4-Chloro-2-{2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (10). From 4-chloro-2-(2-chloroethyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30a**) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (6/94), a dense oil was obtained (75%). ¹H NMR (CDCl₃) δ: 2.70–2.80 (m, 8H, H-pip.), 2.85–2.95 (m, 4H, 2CH₂), 3.05–3.15 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.90 (s, 3H, OCH₃), 4.20 (t, *J* = 6 Hz, 2H, CH₂), 4.35 (t, *J* = 6 Hz, 2H, CH₂), 6.90–7.05 (m, 6H, H-arom.), 7.15–7.35 (m, 2H, H-arom.), 7.65 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 247–250 °C. Anal. calcd for C₂₉H₃₆Cl₂N₆O₃ · 2HCl: C, 52.74; H, 5.76; N, 12.70, found: C, 52.63; H, 6.05; N, 12.46.

4-Chloro-2-{4-[4-(2-chlorophenyl)-1-piperazinyl]butyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (12). From 4-chloro-2-(4-chlorobutyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30b**) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (10/90), a dense oil was obtained (35%). ¹H NMR (CDCl₃) δ: 1.50–1.70 (m, 2H, CH₂), 1.85–2.00 (m, 2H, CH₂), 2.55 (t, *J* = 8 Hz, 2H, CH₂), 2.65–2.75 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.05–3.15 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.90 (s, 3H, OCH₃), 4.10–4.20 (m, 4H, 2CH₂), 6.95–7.10 (m, 6H, H-arom.), 7.15–7.35 (m, 2H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 127–130 °C. Anal. calcd for C₃₁H₄₀Cl₂N₆O₃ · 3HCl: C, 54.10; H, 6.10; N, 12.20, found: C, 54.45; H, 6.41; N, 11.95.

4-Chloro-2-{5-[4-(2-chlorophenyl)-1-piperazinyl]pentyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (13). From 4-chloro-2-(5-bromopentyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30c**) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (7/93), a dense oil was obtained (40%). ¹H NMR (CDCl₃) δ: 1.30–1.45 (m, 2H, CH₂), 1.50–1.70 (m, 2H, CH₂), 1.75–1.85 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.65–2.75 (m, 8H, H-pip.), 2.90 (t, *J* = 6 Hz, 2H, CH₂), 3.05–3.15 (m, 4H, H-pip.), 3.35–3.45 (m, 4H, H-pip.), 3.85 (s, 3H, OCH₃), 4.10–4.20 (m, 4H, 2CH₂), 6.80–6.95 (m, 5H, H-arom.), 7.05 (d, 1H, H-arom.), 7.20 (t, 1H, H-arom.), 7.25–7.35 (m, 1H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 120–123 °C. Anal. calcd for C₃₂H₄₂Cl₂N₆O₃ · 4HCl: C, 49.56; H, 65.42; N, 10.80, found: C, 49.62; H, 5.90; N, 10.95.

4-Chloro-2-{6-[4-(2-chlorophenyl)-1-piperazinyl]hexyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (14). From 4-chloro-2-(6-chlorohexyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30d**) with 1-(2-chlorophenyl)-piperazine.

Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (6/94), a dense oil was obtained (58%). ¹H NMR (CDCl₃) δ: 1.30–1.45 (m, 4H, 2CH₂), 1.55–1.65 (m, 2H, CH₂), 1.75–1.85 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.65–2.75 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.00–3.10 (m, 4H, H-pip.), 3.35–3.45 (m, 4H, H-pip.), 3.85 (s, 3H, OCH₃), 4.10–4.20 (m, 4H, 2CH₂), 6.80–6.95 (m, 5H, H-arom.), 7.05 (d, 1H, H-arom.), 7.20 (t, 1H, H-arom.), 7.25–7.35 (m, 1H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 219–222 °C. Anal. calcd for C₃₃H₄₄Cl₂N₆O₃ · 2HCl: C, 55.00; H, 6.40; N, 11.70, found: C, 55.11; H, 6.54; N, 11.57.

4-Chloro-2-{7-[4-(2-chlorophenyl)-1-piperazinyl]heptyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (15). From 4-chloro-2-(7-bromoheptyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (30e) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (6/94), a dense oil was obtained (75%). ¹H NMR (CDCl₃) δ: 1.30–1.45 (m, 6H, 3CH₂), 1.55–1.65 (m, 2H, CH₂), 1.75–1.85 (m, 2H, CH₂), 2.40 (t, *J* = 8 Hz, 2H, CH₂), 2.60–2.70 (m, 8H, H-pip.), 2.95 (t, 2H, CH₂), 3.00–3.10 (m, 4H, H-pip.), 3.35–3.45 (m, 4H, H-pip.), 3.85 (s, 3H, OCH₃), 4.10–4.20 (m, 4H, 2CH₂), 6.80–6.95 (m, 5H, H-arom.), 7.05 (d, 1H, H-arom.), 7.20 (t, 1H, H-arom.), 7.25–7.35 (m, 1H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride is hygroscopic. Anal. calcd for C₃₄H₄₆Cl₂N₆O₃ · 4HCl: C, 50.82; H, 5.70; N, 10.40, found: C, 50.86; H, 5.80; N, 10.26.

4-Chloro-2-{8-[4-(2-chlorophenyl)-1-piperazinyl]octyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (16). From 4-chloro-2-(8-chlorooctyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (30f) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (6/94), a dense oil was obtained (40%). ¹H NMR (CDCl₃) δ: 1.30–1.45 (m, 8H, 4CH₂), 1.50–1.60 (m, 2H, CH₂), 1.65–1.75 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.60–2.75 (m, 8H, H-pip.), 2.90 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.20 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.85 (s, 3H, OCH₃), 4.10–4.30 (m, 4H, 2CH₂), 6.70–6.90 (m, 5H, H-arom.), 7.05 (d, 1H, H-arom.), 7.20 (t, 1H, H-arom.), 7.25–7.35 (m, 1H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride is hygroscopic. Anal. calcd for C₃₅H₄₈Cl₂N₆O₃ · 3HCl: C, 53.82; H, 6.53; N, 10.76, found: C, 53.91; H, 6.75; N, 10.83.

Compounds **19–22** and **25–28** were prepared using the general method A, starting from 6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**1a**).⁶

2-{4-[4-(2-Methoxyphenyl)-1-piperazinyl]butyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (19). From 2-(4-chlorobutyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31a) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (12/88), a dense oil was obtained (50%).

¹H NMR (CDCl₃) δ: 1.60–1.75 (m, 2H, CH₂), 1.80–1.90 (m, 2H, CH₂), 2.50 (t, *J* = 8 Hz, 2H, CH₂), 2.70–2.80 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.20 (m, 4H, H-pip.), 3.30–3.40 (m, 4H, H-pip.), 3.85 (s, 6H, 2OCH₃), 4.10 (t, *J* = 8 Hz, 2H, CH₂), 4.20 (t, *J* = 6 Hz, 2H, CH₂), 6.80–7.00 (m, 9H, 8H-arom., 1H-pyrid.), 7.10 (d, 1H, H-pyrid.). The corresponding hydrochloride had mp: 125–128 °C. Anal. calcd for C₃₂H₄₄N₆O₄ · 5HCl: C, 50.64; H, 6.46; N, 11.08, found: C, 50.58; H, 6.76; N, 10.95.

2-{5-[4-(2-Methoxyphenyl)-1-piperazinyl]pentyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (20). From 2-(5-bromopentyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31b) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (7/93), a dense oil was obtained (45%). ¹H NMR (CDCl₃) δ: 1.40–1.50 (m, 2H, CH₂), 1.60–1.70 (m, 2H, CH₂), 1.80–1.90 (m, 2H, CH₂), 2.50 (t, *J* = 8 Hz, 2H, CH₂), 2.70–2.80 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.20 (m, 4H, H-pip.), 3.25–3.35 (m, 4H, H-pip.), 3.90 (s, 6H, 2OCH₃), 4.10 (t, *J* = 8 Hz, 2H, CH₂), 4.20 (t, *J* = 6 Hz, 2H, CH₂), 6.80–7.00 (m, 9H, 8H-arom., 1H-pyrid.), 7.10 (d, *J* = 9 Hz, 1H, H-pyrid.). The corresponding hydrochloride had mp: 131–134 °C. Anal. calcd for C₃₃H₄₆N₆O₄ · 5HCl: C, 51.27; H, 6.60; N, 10.80, found: C, 51.47; H, 6.86; N, 10.55.

2-{6-[4-(2-Methoxyphenyl)-1-piperazinyl]hexyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (21). From 2-(6-chlorohexyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31c) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (10/90), a dense oil was obtained (47%). ¹H NMR (CDCl₃) δ: 1.30–1.45 (m, 4H, 2CH₂), 1.60–1.70 (m, 2H, CH₂), 1.80–1.90 (m, 2H, CH₂), 2.45 (t, *J* = 8 Hz, 2H, CH₂), 2.70–2.80 (m, 8H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.10–3.20 (m, 4H, H-pip.), 3.25–3.35 (m, 4H, H-pip.), 3.90 (s, 6H, 2OCH₃), 4.10 (t, *J* = 8 Hz, 2H, CH₂), 4.20 (t, *J* = 6 Hz, 2H, CH₂), 6.80–7.00 (m, 9H, 8H-arom., 1H-pyrid.), 7.10 (d, *J* = 9 Hz, 1H, H-pyrid.). The corresponding hydrochloride had mp: 132–135 °C. Anal. calcd for C₃₄H₄₈N₆O₄ · 5HCl: C, 51.89; H, 6.70; N, 10.60, found: C, 51.75; H, 7.03; N, 10.34.

2-{7-[4-(2-Methoxyphenyl)-1-piperazinyl]heptyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (22). From 2-(7-bromoheptyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31d) with 1-(2-methoxyphenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (10/90), a dense oil was obtained (70%). ¹H NMR (CDCl₃) δ: 1.30–1.45 (m, 6H, 3CH₂), 1.60–1.85 (m, 4H, 2CH₂), 2.70 (t, *J* = 8 Hz, 2H, CH₂), 2.75–2.80 (m, 4H, H-pip.), 2.85–3.00 (m, 6H, 4H-pip., CH₂), 3.20–3.30 (m, 4H, H-pip.), 3.35–3.40 (m, 4H, H-pip.), 3.90 (s, 6H, 2OCH₃), 4.10 (t, *J* = 8 Hz, 2H, CH₂), 4.20 (t, *J* = 6 Hz, 2H, CH₂), 6.85 (d, *J* = 9 Hz, 1H, H-pyrid.), 6.80–7.00 (m, 8H, H-arom.), 7.10 (d, *J* = 9 Hz, 1H, H-pyrid.). The corresponding hydrochloride had mp:

137–140 °C. Anal. calcd for $C_{35}H_{50}N_6O_4 \cdot 5HCl$: C, 52.48; H, 6.87; N, 10.49, found: C, 52.75; H, 6.95; N, 10.64.

2-{4-[4-(2-Chlorophenyl)-1-piperazinyl]butyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (25). From 2-(4-chlorobutyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**31a**) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/ CH_2Cl_2 (13/87), a dense oil was obtained (30%). 1H NMR ($CDCl_3$) δ : 1.55–1.75 (m, 2H, CH_2), 1.80–1.95 (m, 2H, CH_2), 2.55 (t, $J=8$ Hz, 2H, CH_2), 2.65–2.70 (m, 8H, H-pip.), 2.95 (t, $J=6$ Hz, 2H, CH_2), 3.10–3.20 (m, 4H, H-pip.), 3.30–3.40 (m, 4H, H-pip.), 3.90 (s, 3H, OCH_3), 4.10 (t, $J=8$ Hz, 2H, CH_2), 4.25 (t, $J=6$ Hz, 2H, CH_2), 6.85 (d, $J=9$ Hz, 1H, H-pyrid.), 6.90–7.10 (m, 7H, H-arom.), 7.15 (d, $J=9$ Hz, 1H, H-pyrid.), 7.20–7.40 (m, 1H, H-arom.). The corresponding hydrochloride had mp: 115–118 °C. Anal. calcd for $C_{31}H_{41}ClN_6O_3 \cdot 3HCl$: C, 53.90; H, 6.37; N, 12.70, found: C, 53.84; H, 6.20; N, 11.95.

2-{5-[4-(2-Chlorophenyl)-1-piperazinyl]pentyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (26). From 2-(5-bromopentyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**31b**) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/ CH_2Cl_2 (14/86), a dense oil was obtained (35%). 1H NMR ($CDCl_3$) δ : 1.40–1.45 (m, 2H, CH_2), 1.50–1.70 (m, 2H, CH_2), 1.75–1.90 (m, 2H, CH_2), 2.40 (t, $J=8$ Hz, 2H, CH_2), 2.65–2.70 (m, 8H, H-pip.), 2.90 (t, $J=6$ Hz, 2H, CH_2), 3.05–3.15 (m, 4H, H-pip.), 3.30–3.40 (m, 4H, H-pip.), 3.85 (s, 3H, OCH_3), 4.05 (t, $J=8$ Hz, 2H, CH_2), 4.15 (t, $J=6$ Hz, 2H, CH_2), 6.85 (d, $J=9$ Hz, 1H, H-pyrid.), 6.90–7.00 (m, 7H, H-arom.), 7.10 (d, $J=9$ Hz, 1H, H-pyrid.), 7.15–7.35 (m, 1H, H-arom.). The corresponding hydrochloride had mp: 136–138 °C. Anal. calcd for $C_{32}H_{43}ClN_6O_3 \cdot 4HCl$: C, 52.87; H, 6.35; N, 11.30, found: C, 52.76; H, 6.20; N, 10.95.

2-{6-[4-(2-Chlorophenyl)-1-piperazinyl]hexyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (27). From 2-(6-chlorohexyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**31c**) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/ CH_2Cl_2 (15/85), a dense oil was obtained (30%). 1H NMR ($CDCl_3$) δ : 1.35–1.45 (m, 4H, $2CH_2$), 1.55–1.70 (m, 2H, CH_2), 1.75–1.90 (m, 2H, CH_2), 2.50 (t, $J=8$ Hz, 2H, CH_2), 2.65–2.75 (m, 8H, H-pip.), 2.95 (t, $J=6$ Hz, 2H, CH_2), 3.10–3.20 (m, 4H, H-pip.), 3.30–3.40 (m, 4H, H-pip.), 3.85 (s, 3H, OCH_3), 4.05 (t, $J=8$ Hz, 2H, CH_2), 4.20 (t, $J=6$ Hz, 2H, CH_2), 6.85 (d, $J=9$ Hz, 1H, H-pyrid.), 6.90–7.15 (m, 7H, H-arom.), 7.20–7.25 (m, 1H, H-pyrid.), 7.30–7.40 (m, 1H, H-arom.). The corresponding hydrochloride had mp: 127–130 °C. Anal. calcd for $C_{33}H_{45}ClN_6O_3 \cdot 3HCl$: C, 55.10; H, 6.50; N, 11.70, found: C, 55.35; H, 6.81; N, 11.42.

2-{7-[4-(2-Chlorophenyl)-1-piperazinyl]heptyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (28). From 2-(7-bromoheptyl)-6-{4-[2-(2-methoxy-

phenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**31d**) with 1-(2-chlorophenyl)-piperazine. Purified by chromatography on a silica gel column eluting with EtOH/ CH_2Cl_2 (15/85), a dense oil was obtained (65%). 1H NMR ($CDCl_3$) δ : 1.30–1.45 (m, 6H, $3CH_2$), 1.50–1.65 (m, 2H, CH_2), 1.70–1.85 (m, 2H, CH_2), 2.45 (t, $J=8$ Hz, 2H, CH_2), 2.65–2.75 (m, 8H, H-pip.), 2.90 (t, $J=6$ Hz, 2H, CH_2), 3.05–3.15 (m, 4H, H-pip.), 3.25–3.40 (m, 4H, H-pip.), 3.85 (s, 3H, OCH_3), 4.00 (t, $J=8$ Hz, 2H, CH_2), 4.15 (t, $J=6$ Hz, 2H, CH_2), 6.85 (d, $J=9$ Hz, 1H, H-pyrid.), 6.90–7.05 (m, 7H, H-arom.), 7.10 (d, $J=9$ Hz, 1H, H-pyrid.), 7.20–7.35 (m, 1H, H-arom.). The corresponding hydrochloride had mp: 137–140 °C. Anal. calcd for $C_{34}H_{47}ClN_6O_3 \cdot 4HCl$: C, 54.64; H, 6.92; N, 10.27, found: C, 54.10; H, 6.65; N, 10.50.

General method B

4-Chloro-2-{3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (4). To 30 mL of dry ethanol was added (0.1 g, 2.5 mmol) of sodium hydroxide pellets, after was added 4-chloro-5-{4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl}-3(2H)-pyridazinone (**1**) (0.9 g, 2.5 mmol) and the suspension was refluxed under stirring for 30 min, then 1-(2-methoxyphenyl)-4-(3-chloropropyl)-piperazine (**29c**) (0.67 g, 2.5 mmol) dissolved in dry ethanol was added, after the reaction mixture was refluxed under stirring for 15 h. After cooling and evaporation under reduced pressure of the solvent, the residue was purified by chromatography on a silica gel, eluting with EtOH/ CH_2Cl_2 (7/93). A dense oil was obtained (45%). 1H NMR ($CDCl_3$) δ : 1.90–2.10 (m, 2H, CH_2), 2.50 (t, $J=8$ Hz, 2H, CH_2), 2.60–2.80 (m, 8H, H-pip.), 2.90 (t, $J=6$ Hz, 2H, CH_2), 3.05–3.15 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.85 (s, 6H, $2OCH_3$), 4.10–4.30 (m, 4H, $2CH_2$), 6.80–7.00 (m, 8H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride had mp: 113–115 °C. Anal. calcd for $C_{31}H_{41}ClN_6O_4 \cdot 2HCl$: C, 55.57; H, 6.42; N, 12.54, found: C, 55.83; H, 6.65; N, 12.70.

4-Chloro-2-{3-[4-(2-chlorophenyl)-1-piperazinyl]propyl}-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (11). From **1** with 1-(2-chlorophenyl)-4-(3-chloropropyl)-piperazine (**29d**). Purified by chromatography on a silica gel column eluting with EtOH/ CH_2Cl_2 (8/92), a dense oil was obtained (30%). 1H NMR ($CDCl_3$) δ : 2.00–2.15 (m, 2H, CH_2), 2.55 (t, $J=8$ Hz, 2H, CH_2), 2.65–2.75 (m, 4H, H-pip.), 2.75–2.85 (m, 4H, H-pip.), 2.95 (t, $J=6$ Hz, 2H, CH_2), 3.05–3.15 (m, 4H, H-pip.), 3.40–3.50 (m, 4H, H-pip.), 3.90 (s, 3H, OCH_3), 4.15–4.30 (m, 4H, $2CH_2$), 6.90–7.10 (m, 6H, H-arom.), 7.15–7.35 (m, 2H, H-arom.), 7.60 (s, 1H, H-pyrid.). The corresponding hydrochloride is hygroscopic. Anal. calcd for $C_{30}H_{38}Cl_2N_6O_3 \cdot 3HCl$: C, 50.68; H, 5.80; N, 11.60, found: C, 50.28; H, 6.00; N, 11.25.

Compounds **17**, **18**, **23** and **24** were prepared with the same procedure described for compound **4** starting from compound **1a**.

2-{2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone

(17). From **1a** with 1-(2-methoxyphenyl)-4-(2-chloroethyl)-piperazine (**29a**). Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (8/92), a dense oil was obtained (50%). ¹H NMR (CDCl₃) δ: 2.60–2.80 (m, 8H, H-pip.), 2.85–2.90 (m, 4H, 2CH₂), 3.05–3.15 (m, 4H, H-pip.), 3.25–3.40 (m, 4H, H-pip.), 3.85 (s, 6H, 2OCH₃), 4.15–4.30 (m, 4H, 2CH₂), 6.80–6.95 (m, 9H, 8H-arom., 1H-pyrid.), 7.10 (d, *J* = 9 Hz, 1H, H-pyrid.). The corresponding hydrochloride had mp: 231–234 °C. Anal. calcd for C₃₀H₄₀N₆O₄ · 2HCl: C, 57.98; H, 6.76; N, 13.52, found: C, 57.67; H, 6.82; N, 13.70.

2-{3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**18**). From **1a** with 1-(2-methoxyphenyl)-4-(3-chloropropyl)-piperazine (**29c**). Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (10/90), a dense oil was obtained (35%). ¹H NMR (CDCl₃) δ: 2.10–2.20 (m, 2H, CH₂), 2.65–2.80 (m, 8H, H-pip.), 2.85–2.95 (m, 4H, 2CH₂), 3.20–3.30 (m, 4H, H-pip.), 3.35–3.40 (m, 4H, H-pip.), 3.85 (s, 6H, 2OCH₃), 4.10–4.30 (m, 4H, 2CH₂), 6.80–7.00 (m, 9H, 8H-arom., 1H-pyrid.), 7.10 (d, 1H, H-pyrid.). The corresponding hydrochloride is hygroscopic. Anal. calcd for C₃₁H₄₂N₆O₄ · 2HCl: C, 58.60; H, 6.93; N, 13.23, found: C, 58.27; H, 6.63; N, 12.95.

2-{2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**23**). From **1a** with 1-(2-chlorophenyl)-4-(2-chloroethyl)-piperazine (**29b**). Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (12/88), a dense oil was obtained (45%). ¹H NMR (CDCl₃) δ: 2.60–2.70 (m, 8H, H-pip.), 2.75–2.80 (m, 4H, 2CH₂), 2.95–3.05 (m, 4H, H-pip.), 3.20–3.30 (m, 4H, H-pip.), 3.80 (s, 6H, 2OCH₃), 4.05–4.25 (m, 4H, 2CH₂), 6.75 (d, *J* = 9 Hz, 1H, H-pyrid.), 6.90–7.05 (m, 6H, H-arom.), 7.15 (d, *J* = 9 Hz, 1H-pyrid.), 7.20–7.25 (m, 1H, H-arom.), 7.35–7.45 (m, 1H, H-arom.). The corresponding hydrochloride had mp: 228–232 °C. Anal. calcd for C₂₉H₃₇ClN₆O₃ · 2HCl: C, 55.64; H, 6.23; N, 13.43, found: C, 55.73; H, 6.40; N, 13.60.

2-{3-[4-(2-chlorophenyl)-1-piperazinyl]propyl}-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**24**). From **1a** with 1-(2-chlorophenyl)-4-(3-chloropropyl)-piperazine (**29d**). Purified by chromatography on a silica gel column eluting with EtOH/CH₂Cl₂ (12/88), a dense oil was obtained (35%). ¹H NMR (CDCl₃) δ: 2.05–2.25 (m, 2H, CH₂), 2.65–2.75 (m, 6H, 4H-pip., CH₂), 2.80–2.95 (m, 6H, 4H-pip., CH₂), 3.15–3.25 (m, 4H, H-pip.), 3.30–3.40 (m, 4H, H-pip.), 3.85 (s, 3H, OCH₃), 4.10–4.25 (m, 4H, 2CH₂), 6.85 (d, *J* = 9 Hz, 1H, H-pyrid.), 6.90–7.10 (m, 7H, H-arom.), 7.15–7.25 (m, 1H, H-pyrid.), 7.30–7.40 (m, 1H, H-arom.). The corresponding hydrochloride had mp: 189–192 °C. Anal. calcd for C₃₀H₃₉ClN₆O₃ · 2HCl: C, 56.30; H, 6.72; N, 13.13, found: C, 56.11; H, 6.40; N, 12.97.

4-Chloro-2-(2-chloroethyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30a**). This compound was prepared from **1**, with 1,2-dibromoethane in benzene, potassium hydroxide and tetrabutyl

ammonium bromide (TBAB) using the method of Yamada.⁹ The residue was purified by chromatography on a silica gel using EtOH/CH₂Cl₂ (4/96) (35%). ¹H NMR (CDCl₃) δ: 2.70–2.85 (m, 4H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.40–3.50 (m, 4H, H-pip.), 3.70 (t, *J* = 6 Hz, 2H, CH₂), 3.85 (s, 3H, OCH₃), 4.20 (t, *J* = 6 Hz, 2H, CH₂), 4.50 (t, *J* = 6 Hz, 2H, CH₂), 6.85–6.95 (m, 4H, H-arom.), 7.65 (s, 1H, H-pyrid.).

General method C

4-Chloro-2-(4-chlorobutyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30b**). A mixture of 1 g (20 mmol) of **1**, 1-bromo-4-chlorobutane (0.7 g, 30 mmol), dry potassium carbonate (0.56 g, 30 mmol) in 20 mL of the acetone, was refluxed under stirring for 15 h. After the filtered residue was evaporated under reduced pressure and was purified by chromatography on silica gel eluting with EtOH/CH₂Cl₂ (3/97) (70%). ¹H NMR (CDCl₃) δ: 1.75–2.05 (m, 4H, 2CH₂), 2.70–2.80 (m, 4H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.40–3.50 (m, 4H, H-pip.), 3.60 (t, *J* = 6 Hz, 2H, CH₂), 3.85 (s, 3H, OCH₃), 4.10–4.25 (m, 4H, 2CH₂), 6.80–7.00 (m, 4H, H-arom.), 7.60 (s, 1H, H-pyrid.).

Compounds **30c–f** were prepared using the method described for compound **30b**.

4-Chloro-2-(5-bromopentyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30c**). From **1** with 1,5-dibromopentane, reaction time 6 h, (50%). ¹H NMR (CDCl₃) δ: 1.40–1.60 (m, 2H, CH₂), 1.70–2.00 (m, 4H, 2CH₂), 2.70–2.80 (m, 4H, H-pip.), 2.90 (t, *J* = 6 Hz, 2H, CH₂), 3.35–3.55 (m, 6H, 4H-pip., CH₂), 3.90 (s, 3H, OCH₃), 4.10–4.30 (m, 4H, 2CH₂), 6.80–7.00 (m, 4H, H-arom.), 7.60 (s, 1H, H-pyrid.).

4-Chloro-2-(6-chlorohexyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30d**). From **1** with 1-bromo-6-chlorohexane, reaction time 8 h, (50%). ¹H NMR (CDCl₃) δ: 1.30–1.35 (m, 4H, 2CH₂), 1.70–1.90 (m, 4H, 2CH₂), 2.70–2.80 (m, 4H, H-pip.), 2.90 (t, *J* = 6 Hz, 2H, CH₂), 3.35–3.55 (m, 6H, 4H-pip., CH₂), 3.90 (s, 3H, OCH₃), 4.10–4.25 (m, 4H, 2CH₂), 6.80–7.00 (m, 4H, H-arom.), 7.60 (s, 1H, H-pyrid.).

4-Chloro-2-(7-bromoheptyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30e**). From **1** with 1,7-dibromoheptane, reaction time 7 h, (75%). ¹H NMR (CDCl₃) δ: 1.30–1.50 (m, 6H, 3CH₂), 1.70–1.90 (m, 4H, 2CH₂), 2.70–2.80 (m, 4H, H-pip.), 2.90 (t, *J* = 6 Hz, 2H, CH₂), 3.40–3.50 (m, 6H, 4H-pip., CH₂), 3.85 (s, 3H, OCH₃), 4.05–4.20 (m, 4H, 2CH₂), 6.80–7.00 (m, 4H, H-arom.), 7.60 (s, 1H, H-pyrid.).

4-Chloro-2-(8-bromooctyl)-5-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2*H*)-pyridazinone (**30f**). From **1** with 1,8-dibromooctane, reaction time 18 h, (50%). ¹H NMR (CDCl₃) δ: 1.20–1.45 (m, 8H, 4CH₂), 1.60–1.90 (m, 4H, 2CH₂), 2.75–2.85 (m, 4H, H-pip.), 2.95 (t, *J* = 6 Hz, 2H, CH₂), 3.25–3.50 (m, 6H, 4H-pip., CH₂), 3.90 (s, 3H, OCH₃), 4.00–4.20 (m, 4H, 2CH₂), 6.80–7.00 (m, 4H, H-arom.), 7.60 (s, 1H, H-pyrid.).

Compounds **31a–d** were prepared using the general method C starting compound **1a**.

2-(4-Chlorobutyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31a). Reaction time 20 h, (70%). ¹H NMR (CDCl₃) δ: 1.50–2.00 (m, 4H, 2CH₂), 2.70–2.85 (m, 4H, H-pip.), 3.00 (t, *J*=6 Hz, 2H, CH₂), 3.30–3.40 (m, 4H, H-pip.), 3.60 (t, *J*=8 Hz, 2H, CH₂), 3.90 (s, 3H, OCH₃), 4.10 (t, *J*=8 Hz, 2H, CH₂), 4.20 (t, *J*=6 Hz, 2H, CH₂), 6.80 (d, *J*=9 Hz, 1H, H-pyrid.), 6.90–7.00 (m, 4H, H-arom.), 7.10 (d, *J*=9 Hz, 1H, H-pyrid.).

2-(5-Bromopentyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31b). Reaction time 20 h, (70%). ¹H NMR (CDCl₃) δ: 1.40–1.60 (m, 2H, CH₂), 1.75–2.00 (m, 4H, 2CH₂), 2.70–2.85 (m, 4H, H-pip.), 2.95 (t, *J*=6 Hz, 2H, CH₂), 3.30–3.50 (m, 6H, 4H-pip., CH₂), 3.90 (s, 3H, OCH₃), 4.05 (t, *J*=8 Hz, 2H, CH₂), 4.25 (t, *J*=6 Hz, 2H, CH₂), 6.85 (d, 1H, H-pyrid.), 6.90–7.00 (m, 4H, H-arom.), 7.10 (d, 1H, H-pyrid.).

2-(6-Chlorohexyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31c). Reaction time 18 h, (70%). ¹H NMR (CDCl₃) δ: 1.30–1.50 (m, 4H, 2CH₂), 1.75–1.90 (m, 4H, 2CH₂), 2.70–2.80 (m, 4H, H-pip.), 3.00 (t, *J*=6 Hz, 2H, CH₂), 3.30–3.40 (m, 4H, H-pip.), 3.55 (t, *J*=8 Hz, H, CH₂), 3.90 (s, 3H, OCH₃), 4.05 (t, *J*=8 Hz, 2H, CH₂), 4.25 (t, *J*=6 Hz, 2H, CH₂), 6.85 (d, *J*=9 Hz, 1H, H-pyrid.), 6.90–7.00 (m, 4H, H-arom.), 7.10 (d, *J*=9 Hz, 1H, H-pyrid.).

2-(7-Bromoheptyl)-6-{4-[2-(2-methoxyphenoxy)ethyl]-1-piperazinyl}-3(2H)-pyridazinone (31d). Reaction time 20 h, (50%). ¹H NMR (CDCl₃) δ: 1.30–1.50 (m, 6H, 3CH₂), 1.70–1.90 (m, 4H, 2CH₂), 2.70–2.80 (m, 4H, H-pip.), 2.90 (t, *J*=6 Hz, 2H, CH₂), 3.30–3.50 (m, 6H, 4H-pip., CH₂), 3.95 (s, 3H, OCH₃), 4.05 (t, *J*=8 Hz, 2H,

CH₂), 4.20 (t, *J*=6 Hz, 2H, CH₂), 6.80 (d, *J*=9 Hz, 1H, H-pyrid.), 6.90–7.00 (m, 4H, H-arom.), 7.10 (d, *J*=9 Hz, 1H, H-pyrid.).

Acknowledgements

Financial support (40%) provided by the Ministry of University and Scientific and Technological Research (MURST) is acknowledged. Thanks are due to Dr. C. Santi for NMR analysis and the aid in the structure elucidation.

References

1. Strader, C. D.; Sigal, I. S.; Dixon, R. A. F. *Faseb, J* **1989**, *3*, 1825.
2. Strader, C. D.; Sigal, I. S.; Dixon, R. A. F. *Trends Pharmacol. Sci.* **1989**, Dec. suppl. 26, 30.
3. (a) Kasztreiner, E.; Matyus, P.; Rabloczky, G.; Jaszlits, L. *Drugs Future* **1989**, *14*, 62. (b) Curran, W. V.; Ross, A. *J. Med. Chem.* **1974**, *17*, 273.
4. Hieble, J. P.; Boyce, A. J.; Caine, M. *Fed. Proc.* **1986**, *45*, 2609.
5. Corsano, S.; Scapicchi, R.; Strappaghetti, G.; Marucci, G.; Paparelli, F. *Eur. J. Med. Chem.* **1993**, *28*, 647.
6. Corsano, S.; Strappaghetti, G.; Codagnone, A.; Scapicchi, R.; Marucci, G. *Eur. J. Med. Chem.* **1992**, *27*, 545.
7. Gerge, P.; Borg, S.; O'Connor, S.; et al. *Eur. J. Med. Chem.* **1995**, *30*, 299.
8. Corsano, S.; Strappaghetti, G.; Scapicchi, R.; De Blasi, A.; Barbarulo, D. *Abstracts of Papers*, 2nd Congress Chim. Pharm., Ferrara, **1995**.
9. Yamada, T.; Tsukamoto, Y.; Shimamura, H.; Banno, S.; Sapo, M. *Eur. J. Med. Chem.* **1993**, *18*, 209.
10. Bourdais, J. *Bull. Soc. Chim. de France* **1968**, *8*, 3246.
11. Cheng, Y. C.; Prusoff, W. H. *Biochem. Pharmacol.* **1973**, *22*, 3099.
12. Lowry, O. H.; Rosenbrough, N. J.; Farr, A. L.; Randall, R. J. *J. Biol. Chem.* **1951**, *193*, 265.